Noked Capital’s XTL Biopharmaceuticals XTLB Stock Holding History

Noked Capital’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$221	Hold	49,722	–	–	0.02%	43
2022 Q2	$302K	Hold	49,722	–	–	0.07%	43
2022 Q1	$471K	Hold	49,722	–	–	0.14%	34
2021 Q4	$551K	Hold	49,722	–	–	0.14%	38
2021 Q3	$871K	Hold	49,722	–	–	0.2%	33
2021 Q2	$794K	Hold	49,722	–	–	0.2%	26
2021 Q1	$662K	Hold	49,722	–	–	0.22%	28
2020 Q4	$603	Hold	49,722	–	–	0.25%	25
2020 Q3	$378K	Hold	49,722	–	–	0.25%	21
2020 Q2	$316K	Hold	49,722	–	–	0.23%	15
2020 Q1	$234K	Hold	49,722	–	–	0.42%	13
2019 Q4	$272K	Hold	49,722	–	–	0.31%	43
2019 Q3	$286K	Hold	49,722	–	–	0.3%	37
2019 Q2	$398K	Hold	49,722	–	–	0.49%	23
2019 Q1	$469K	Hold	49,722	–	–	0.49%	42
2018 Q4	$344K	Buy	+49,722	New	+$467K	0.29%	47

Other funds holding XTLB

Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Noked Capital's XTLB Position: Q3 2022 in Review

Noked Capital held its XTL Biopharmaceuticals (XTLB) position steady in Q3 2022 at 49,722 shares worth $221. The position accounts for 0.02% of the portfolio, ranked #43.

Noked Capital first reported a position in XTLB in Q4 2018 and has held it in 16 quarters since. The position peaked at $871K in Q3 2021. 3 funds tracked by Wall St. Rank hold XTLB as of Q3 2022.

Noked Capital held 49,722 shares of XTL Biopharmaceuticals worth $221 as of Q3 2022.
Noked Capital left its XTL Biopharmaceuticals share count unchanged in Q3 2022.
XTL Biopharmaceuticals made up 0.02% of Noked Capital's portfolio in Q3 2022, its #43 holding.
Noked Capital first reported a position in XTL Biopharmaceuticals in Q4 2018 and has held it in 16 quarters since.
Noked Capital's XTL Biopharmaceuticals position peaked at $871K in Q3 2021.
3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q3 2022.

Based on Noked Capital's 13F filing for Q3 2022, filed 14 Nov 2022.